SCHEMBL13648235

SCHEMBL13648235

CNC(=O)c1cc(Oc2cccc(NNC(=O)Nc3cccc(C(F)(F)F)c3)c2)ccn1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.78
RET P07949 4/20 0.78
MAPK14 Q16539 4/20 0.78
TNNI3K Q59H18 3/20 0.78
ABL1 P00519 3/20 0.78
EPHA2 P29317 3/20 0.78
MAP3K20 Q9NYL2 3/20 0.78
PLK4 O00444 2/20 0.78
AURKA O14965 2/20 0.78
MAPK13 O15264 2/20 0.78
MAP4K4 O95819 2/20 0.78
LCK P06239 2/20 0.78
FYN P06241 2/20 0.78
LYN P07948 2/20 0.78
SRC P12931 2/20 0.78
RPS6KB1 P23443 2/20 0.78
AXL P30530 2/20 0.78
FRK P42685 2/20 0.78
MAPK9 P45984 2/20 0.78
BLK P51451 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648025 0.93 KDR (0.72) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648323 0.89 KDR (0.70) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648050 0.88 KDR (0.69) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648346 0.88 KDR (0.74) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648300 0.88 KDR (0.61) KDRRETMAPK14TNNI3KABL1
SCHEMBL14422924 0.87 KDR (0.75) KDRRETMAPK14TNNI3KABL1
SCHEMBL16628085 0.87 KDR (1.00) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648241 0.87 RAF1 (0.74) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648130 0.87 RET (0.88) KDRRETMAPK14TNNI3KABL1
SCHEMBL13648030 0.85 RET (0.59) KDRRETMAPK14TNNI3KABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253688-A1 Semicarbazide derivatives as kinase inhibitors MERCK PATENT GMBH (DE) 2009-10-08 US disclosed
US-20090253688-A1 Semicarbazide derivatives as kinase inhibitors MERCK PATENT GMBH (DE) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253688-A1 Semicarbazide derivatives as kinase inhibitors MAP3K1, MAP3K6, MAP3K2 KDR 658/4885RET 117/4885MAPK14 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.